Aeglea Biotherapeutics (AGLE) Received its Third Buy in a Row

After Needham and H.C. Wainwright gave Aeglea Biotherapeutics (NASDAQ: AGLE) a Buy rating last month, the company received another Buy, this time from Evercore ISI. Analyst Joshua Schimmer maintained a Buy rating on Aeglea Biotherapeutics yesterday and set a price target of $26.00. The company’s shares closed last Monday at $8.04.

According to, Schimmer is a 5-star analyst with an average return of 8.9% and a 49.3% success rate. Schimmer covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Madrigal Pharmaceuticals, and Adamas Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aeglea Biotherapeutics with a $19.00 average price target, a 143.6% upside from current levels. In a report issued on November 8, H.C. Wainwright also reiterated a Buy rating on the stock with a $20.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.45 and a one-year low of $5.99. Currently, Aeglea Biotherapeutics has an average volume of 50.32K.

Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGLE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which engages in the design and development of human enzyme therapeutics for patients with rare genetic diseases and cancer. It develops pegzilarginase, its lead investigational therapy for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts